Cromo-Comod

Cromo-Comod Uses, Dosage, Side Effects, Food Interaction and all others data.

A chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.

Cromoglicate or cromolyn (USAN), a synthetic compound, inhibits antigen-induced bronchospasms and, hence, is used to treat asthma and allergic rhinitis. Cromoglicate is used as an ophthalmic solution to treat conjunctivitis and is taken orally to treat systemic mastocytosis and ulcerative colitis.

Cromo-Comod
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Cromo-Comod
Generic	Cromoglicic acid
Cromoglicic acid Other Names	Acide Cromoglicique, Acido Cromoglicico, Acidum Cromoglicicum, Cromoglicate, Cromoglicic acid, Cromoglycate, Cromoglycic acid, Cromolyn
Type
Formula	C₂₃H₁₆O₁₁
Weight	Average: 468.3665 Monoisotopic: 468.069261354
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Cromo-Comod is a medication used to treat asthma, allergic reactions of the eyes and nose, as well as other mast cell reactions.

For the management of patients with bronchial asthma. Also used in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

Cromo-Comod is also used to associated treatment for these conditions: Asthma, Conjunctivitis, Vernal, Exercise-Induced Bronchospasm, Food Allergy, Keratoconjunctivitis, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Conjunctivitis, Seasonal Allergic Rhinitis, Urticaria Pigmentosa, Vernal Keratoconjunctivitis

How Cromo-Comod works

Cromoglicate inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Cromoglicate also may reduce the release of inflammatory leukotrienes. Cromoglicate may act by inhibiting calcium influx.